-
Alexion recently received two awards in recognition of the Company’s significant revenue growth in recent years and for its status as one of the fastest growing companies in the tri-state area of Connecticut, New York, and New Jersey.
-
Alexion is working with physicians and researchers around the world to develop new therapies for patients with severe, life-threatening and often ultra-rare diseases. Learn more about our research and development programs and clinical trials underway.
-
Alexion has a long-standing commitment to energy conservation and to the communities in which it operates. The company recently installed a solar PV system on the rooftop of its corporate headquarters and research facility in Cheshire, Conn. This system will produce more than 329,000 kWh of power annually, resulting in an estimated reduction of 380,000 lbs of CO2 emissions per year.
-
Soliris® (eculizumab) is the first therapy approved for
the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Visit
the new Soliris site,
www.soliris.net
, to learn more about Soliris and PNH, read patient stories,
join our patient support program and get updates on the latest research.
-
Alexion is now hiring for a range of positions, from marketing to research and development and support functions. We’re looking for people who share our passion and commitment to transforming the lives of patients with life-threatening ultra-rare diseases. We invite you to learn more about our company and our culture by meeting our team and reviewing our career opportunities.